Follow Feed 커뮤니티에서 거래자 및 투자자와 연결하세요.
포괄적인 옵션 데이터를 탐색하고 옵션 흐름으로 고급 필터를 사용하세요.
터미널 모니터로 주식 및 자산 관심 목록을 구성하고 모니터링하세요.
Après l’Acidose Tubulaire Rénale distale en décembre 2022, ADV7103 obtient le statut « médicament orphelin » aux Etats-Unis dans la cystinurie...
Subscription of €5.7 million representing 95% of the initial amount Cemag Invest and Bpifrance now own respectively 18.0% and 21.6% of equity...
Capital increase with pre-emptive subscription rights ("PSR") for an initial amount of €6.0 million, which may be increased to €6.9 million if...
Sibnayal® (potassium citrate/potassium bicarbonate) has been launched on March 1, 2023 Reference price equals to an annual treatment cost of...
Sales of Sibnayal® reached 1.4 million euros, a significant increase of 40% over one year Significant growth acceleration in H2 2022 Regulatory...
Regulatory News: Advicenne (Euronext Growth Paris ALDVI - FR0013296746), a specialty pharmaceutical company dedicated to developing and...
Regulatory News: Advicenne (Euronext Growth Paris ALDVI - FR0013296746) (Paris:ALDVI), société pharmaceutique spécialisée dans le développement...
Hausse de 15% des ventes de Sibnayal à 0,64 million d’euros Lancement commercial de Sibnayal® en Europe avec des commandes de plus de 75...
귀하가 조회한 주식이 이 박스에 나타나며 쉽게 최근 시세로 돌아갈 수 있습니다.
도움 및 지원받기: kr-support@advfn.com
ADVFN 서비스 이용은 ADVFN의 이용약관에 동의하는 것입니다 이용약관